TY - JOUR T1 - 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00395-2018 VL - 52 IS - 1 SP - 1800395 AU - Yibeltal Assefa AU - Yalemzewod Assefa AU - Solomon Woldeyohannes AU - Yohhei Hamada AU - Haileyesus Getahun Y1 - 2018/07/01 UR - http://erj.ersjournals.com/content/52/1/1800395.abstract N2 - One-third to one-quarter of the world's population is estimated to have latent tuberculosis infection (LTBI) [1]. These infected persons are at risk for developing active disease with a lifetime risk of reactivation estimated to be 5–10% [2]. Prevention of reactivation of LTBI in population groups with higher risk of progression to active disease than the general population, is critical to end the global TB epidemic [3].Treatment of latent tuberculosis infection in children with a 3-month daily rifampicin and isoniazid regimen is safe with better compliance, adherence and completion rate than a 6- or 9-month isoniazid monotherapy http://ow.ly/x28Z30jDfCE ER -